Industry News
Biotechnology Industry News
Novo Nordisk’s GLP-1/amylin…
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had previously laid out for
H1 CEO Ariel Katz shares how AI,…
H1 CEO Ariel Katz shares how AI, regulation and pricing shifts are changing clinical trials and commercialization.
Wave Life Sciences has the fate of…
Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not to take over development of WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency (AATD),
Daiichi Sankyo’s development of…
Daiichi Sankyo’s development of ADCs continues to hit turbulence. The company has experienced two latest hiccups: the discontinuation of internal development of a next-wave candidate featuring its second ADC platform, and yet another delay for
Having already secured regional…
Having already secured regional rights to vTv Therapeutics’ inflammation drug, China’s Newsoara is fronting $20 million to take ownership of the clinical-stage asset across the rest of the world.
Skye Bioscience has published…
Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% total weight loss as it works to recover from its failure to hit the primary endpoint.
Roche is continuing its return to…
Roche is continuing its return to the RNAi space by paying $200 million for the worldwide license to one of SanegeneBio’s programs.
Sanofi’s pipeline features a…
Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the latest mixed phase 3 data from venglustat continue this trend.
As biotech and other sectors of…
As biotech and other sectors of the life sciences industry espouse cautious optimism for a stabler financing environment in 2026, the steady influx of new funds in the space suggests things are trending in a
The FDA warned Corcept…
The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for approval, contradicting the biotech’s claims that the candidate’s eventual rejection came as a shock.
Moderna Chief Medical Officer…
Moderna Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. Meanwhile, the mRNA specialist is welcoming a new chief development officer in the form of
Chugai Pharmaceutical has dropped…
Chugai Pharmaceutical has dropped its only clinical candidate that was developed with the aid of its artificial intelligence drug discovery tool but is not giving up on the technology as a method to power its
Amgen has terminated its…
Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.
The ink was barely dry on…
The ink was barely dry on AstraZeneca’s announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion to one of its regional partners.
Moderna has out-licensed a rare…
Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.
Cardiff is churning its leadership…
Cardiff is churning its leadership team as the biotech advances its colorectal cancer candidate onvansertib toward late-stage clinical development. CEO Mark Erlander, Ph.D., and Chief Financial Officer James Levine are both stepping down from their
Henlius CEO Jason Zhu shares how…
Henlius CEO Jason Zhu shares how the biotech balances biosimilars, innovation and global scale.
AI-fueled Formation Bio has inked…
AI-fueled Formation Bio has inked another licensing deal for a China asset, this time picking up an oral small molecule designed to treat autoimmune disease in a deal worth up to $500 million biobucks.
Two and a half years after Sanofi…
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
Roche has waved goodbye to an…
Roche has waved goodbye to an inflammation drug from Kiniksa—as well as the $100 million the pharma paid for the therapy.